Skip to content
Vaishali Pharma logo

Vaishali Pharma

VAISHALI NSE
₹6.73 −0.06 (−0.88%)
P/E
19.79
View as Markdown
MCP
Close 4 Nov 2026 ₹6.73 −3.11 −31.6% 1Y
Start ₹9.84

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
—
Debt to Equity
0.28
EPS (TTM)
₹0.34
Book Value
₹5.79
Market Cap
—
P/E (TTM)
19.79
P/B
1.16
ROE
6.02%
Dividend Yield
0.00%
EBITDA
₹7.90 Cr
52W High
₹10.20
52W Low
₹4.75
Day Range
₹6.63 – ₹6.88
Volume
68,772

Peer Comparison

Healthcare › Pharmaceuticals

Vaishali Pharma peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Vaishali Pharma (this company)
₹6.7319.79₹92 Cr1.160.00%6.02%—₹108 Cr₹4 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.44%16.25%17.80%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

42 Weak

Data confidence 89/100

Category scores

Quality
32
Poor
Returns, margins, earnings quality 24% weight
Valuation
46
Average
Cheap vs sector & own history 26% weight
Financial Health
46
Average
Solvency, leverage, coverage 10% weight
Momentum
37
Poor
Trend strength, vol-adjusted 13% weight
Ownership
56
Good
FII/DII/promoter flows 26% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

4
  • Promoter holding has decreased over last quarter: -1.07%
  • Promoter holding is low: 30.5%
  • Earnings include an other income of Rs.3.57 Cr.
  • Company has high debtors of 170 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1252
OscillatorsNeutral252
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
33.79
Neutral
MACD (12,26,9)
−0.42
Bearish
SMA (50)
7.97
Bearish
SMA (200)
7.55
Bearish

As of

Growth Rate

Annual windows: Fewer than two fiscal years are reported, so there is no annual growth yet.

Trailing twelve months: Fewer than eight quarters are reported, so there is no trailing-twelve-month figure.

Quarterly Results

₹ Cr
VAISHALI quarterly results, ₹ crore
Particulars Sep 2025Dec 2025Mar 2026Jun 2026
Sales
33.45
24.65
26.93
22.89
Expenses
32.06
23.09
27.13
21.4
Operating Profit
1.39
1.56
−0.2
1.49
OPM %
4.16%
6.33%
−0.74%
6.51%
Other Income
0.84
0.89
1.26
0.58
Interest
0.4
0.51
0.72
0.2
Depreciation
0.17
0.13
0.16
0.14
PBT
1.66
1.81
0.18
1.73
Tax %
28.31%
28.18%
−61.11%
13.87%
Net Profit
1.19
1.32
0.41
1.55
EPS (₹)
0.09
0.1
0.03
0.12

Profit & Loss

₹ Cr
VAISHALI profit and loss, annual, ₹ crore
Particulars Mar 2026TTM
Sales
109
108
Expenses
105
104
Operating Profit
4
4
OPM %
3.8%
3.9%
Other Income
4
4
Interest
2
2
Depreciation
1
1
PBT
5
5
Tax %
25%
—
Net Profit
4
4
EPS (₹)
0.32
0.34
Div. Payout %
0%
—

Balance Sheet

₹ Cr
VAISHALI balance sheet, annual, ₹ crore
Particulars Mar 2026
Equity Capital
26
Reserves
43
Borrowings
19
Other Liabilities
35
Total Liabilities
123
Fixed Assets
2
CWIP
0
Investments
6
Other Assets
116
Total Assets
123

Cash Flow

₹ Cr
VAISHALI cash flow, annual, ₹ crore
Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating
−7
−4
5
0
−9
4
3
2
1
1
1
−18
Investing
0
2
3
1
1
0
0
0
−1
0
1
0
Financing
6
2
−8
−1
8
−4
−3
−2
0
−2
−1
18
Net Cash Flow
−1
0
0
0
0
0
0
0
1
0
1
0
Free Cash Flow
−8
−5
5
0
−10
4
3
2
0
1
1
−18
CFO/OP
−276
1,252
842
16
−326
212
433
78
31
28
185
−3,104

Ratios

VAISHALI financial ratios, annual
Particulars Mar 2026
Debtor Days
170
Inventory Days
13
Days Payable
81
Cash Conversion Cycle
102
Working Capital Days
212

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Vaishali Pharma insights

59 extracted metrics across FY14–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 62.23%
  • Promoters 31.61%
  • Others 6.16%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Vaishali Pharma

What does Vaishali Pharma Ltd do?
Incorporated in 1989, Vaishali Pharma Ltd does marketing of pharmaceutical products including active pharmaceutical ingredients
Where is Vaishali Pharma Ltd (VAISHALI) listed?
Vaishali Pharma Ltd trades as VAISHALI on the NSE.
Which sector does Vaishali Pharma Ltd belong to?
Vaishali Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Vaishali Pharma Ltd?
Vaishali Pharma Ltd trades at a PE ratio of 19.79 as of 4 Nov 2026, on earnings per share of ₹0.34, against a book value of ₹5.79 per share.
What is the 52-week high and low of Vaishali Pharma Ltd?
Over the last 52 weeks Vaishali Pharma Ltd has traded between ₹4.75 and ₹10.2 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Vaishali Pharma Ltd?
Vaishali Pharma Ltd reported a return on equity of 6.02%. Its debt-to-equity ratio is 0.28.

Company Information

Incorporated in 1989, Vaishali Pharma Ltd does marketing of pharmaceutical products including active pharmaceutical ingredients

Listed 15 Jan 2020
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VAISHALI.md for Vaishali Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month